Medigene AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDGEF research report →
About the company
Medigene AG is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of T-cell therapies for the treatment of cancer. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
- CEO
- Ralph Schaefer
- IPO
- 2013
- Employees
- 87
- HQ
- Martinsried, BY, DE
Price Chart
- Market Cap
- $38.17M
- P/E
- -0.10
- P/S
- 0.33
- P/B
- 0.08
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
- Gross Margin
- 72.77%
- Op Margin
- -267.63%
- Net Margin
- -268.10%
- ROE
- -55.69%
- ROIC
- -61.86%
- Revenue
- $6.03M · -80.69%
- Net Income
- $-16,177,000 · -94.20%
- EPS
- $-1.32 · -106.25%
- Op Income
- $-16,149,000
- FCF YoY
- -243.89%
- 52W High
- $2.59
- 52W Low
- $0.10
- 50D MA
- $2.59
- 200D MA
- $2.59
- Beta
- 1.36
- Avg Volume
- 5.71K
Get TickerSpark's AI analysis on MDGEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MDGEF coverage
Recent articles, reports, and earnings notes.
No research on MDGEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDGEF report →Similar companies
Peers in the same neighborhood.